HC Wainwright Issues Optimistic Estimate for COLL Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Investment analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for shares of Collegium Pharmaceutical in a report issued on Monday, March 24th. HC Wainwright analyst O. Livnat now expects that the specialty pharmaceutical company will earn $1.75 per share for the quarter, up from their previous forecast of $1.61. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q4 2025 earnings at $1.82 EPS, FY2025 earnings at $6.26 EPS and FY2026 earnings at $6.36 EPS.

Several other research analysts also recently weighed in on COLL. Piper Sandler decreased their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $29.96 on Thursday. The firm’s 50 day moving average price is $30.51 and its 200-day moving average price is $32.52. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock has a market capitalization of $943.32 million, a PE ratio of 12.91 and a beta of 0.99. Collegium Pharmaceutical has a twelve month low of $27.28 and a twelve month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds have recently made changes to their positions in the business. New Age Alpha Advisors LLC bought a new stake in Collegium Pharmaceutical during the 4th quarter valued at approximately $40,000. TD Private Client Wealth LLC grew its holdings in Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares in the last quarter. KBC Group NV raised its position in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after buying an additional 982 shares during the last quarter. Virtus Fund Advisers LLC lifted its holdings in shares of Collegium Pharmaceutical by 30.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 565 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 316 shares during the last quarter.

Insiders Place Their Bets

In other news, EVP Scott Dreyer sold 2,255 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares of the company’s stock, valued at $3,732,630. This represents a 1.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 109,193 shares of company stock worth $3,243,594. Company insiders own 3.98% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.